340 related articles for article (PubMed ID: 16844285)
1. Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group.
Schips L; Dalpiaz O; Lipsky K; Langner C; Rehak P; Puerstner P; Pummer K; Zigeuner R
Eur Urol; 2007 Jan; 51(1):168-73; discussion 174. PubMed ID: 16844285
[TBL] [Abstract][Full Text] [Related]
2. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer.
Feldman AL; Tamarkin L; Paciotti GF; Simpson BW; Linehan WM; Yang JC; Fogler WE; Turner EM; Alexander HR; Libutti SK
Clin Cancer Res; 2000 Dec; 6(12):4628-34. PubMed ID: 11156212
[TBL] [Abstract][Full Text] [Related]
3. Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma.
Feldman AL; Alexander HR; Yang JC; Linehan WM; Eyler RA; Miller MS; Steinberg SM; Libutti SK
Cancer; 2002 Oct; 95(8):1637-43. PubMed ID: 12365010
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma.
Jacobsen J; Rasmuson T; Grankvist K; Ljungberg B
J Urol; 2000 Jan; 163(1):343-7. PubMed ID: 10604387
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis and other markers for prediction of survival in metastatic renal cell carcinoma.
Alamdari FI; Rasmuson T; Grankvist K; Ljungberg B
Scand J Urol Nephrol; 2007; 41(1):5-9. PubMed ID: 17366095
[TBL] [Abstract][Full Text] [Related]
6. [Clinical significance of serum levels of endostatin in patients with clear cell renal cell carcinoma].
Guan KP; Xiao ZD; Wang D; Shi HZ; Guan YY; Lu L; Han SJ; Li CL
Zhonghua Wai Ke Za Zhi; 2009 May; 47(10):737-9. PubMed ID: 19615205
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma.
Poon RT; Ho JW; Tong CS; Lau C; Ng IO; Fan ST
Br J Surg; 2004 Oct; 91(10):1354-60. PubMed ID: 15376182
[TBL] [Abstract][Full Text] [Related]
8. Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma.
Bono P; Teerenhovi L; Joensuu H
Cancer; 2003 Jun; 97(11):2767-75. PubMed ID: 12767089
[TBL] [Abstract][Full Text] [Related]
9. Early increase in serum levels of the angiogenesis-inhibitor endostatin and of basic fibroblast growth factor in melanoma patients during disease progression.
Kurschat P; Eming S; Nashan D; Krieg T; Mauch C
Br J Dermatol; 2007 Apr; 156(4):653-8. PubMed ID: 17263813
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of endostatin, vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in patients with acute myocardial infarction undergoing early reperfusion therapy.
Seko Y; Fukuda S; Nagai R
Clin Sci (Lond); 2004 May; 106(5):439-42. PubMed ID: 14965340
[TBL] [Abstract][Full Text] [Related]
11. Different vascular endothelial growth factor (VEGF), VEGF-receptor 1 and -2 mRNA expression profiles between clear cell and papillary renal cell carcinoma.
Ljungberg BJ; Jacobsen J; Rudolfsson SH; Lindh G; Grankvist K; Rasmuson T
BJU Int; 2006 Sep; 98(3):661-7. PubMed ID: 16925769
[TBL] [Abstract][Full Text] [Related]
12. Altered expression of vascular endothelial growth factor, fibroblast growth factor-2 and endostatin in patients with hepatocellular carcinoma.
Uematsu S; Higashi T; Nouso K; Kariyama K; Nakamura S; Suzuki M; Nakatsukasa H; Kobayashi Y; Hanafusa T; Tsuji T; Shiratori Y
J Gastroenterol Hepatol; 2005 Apr; 20(4):583-8. PubMed ID: 15836707
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
Braybrooke JP; O'Byrne KJ; Propper DJ; Blann A; Saunders M; Dobbs N; Han C; Woodhull J; Mitchell K; Crew J; Smith K; Stephens R; Ganesan TS; Talbot DC; Harris AL
Clin Cancer Res; 2000 Dec; 6(12):4697-704. PubMed ID: 11156222
[TBL] [Abstract][Full Text] [Related]
14. [Effects of chemotherapy on circulating angiogenic factor levels in patients with breast cancer].
Tang JH; Zhao JH; Gong JP; Qin JW; Pan LQ; Xu ZY
Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):210-4. PubMed ID: 17649639
[TBL] [Abstract][Full Text] [Related]
15. Angiogenic factors: vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b-FGF) are not necessarily elevated in patients with advanced renal cell carcinoma.
Edgren M; Lennernäs B; Larsson A; Kälkner KM
Anticancer Res; 2001; 21(2B):1423-9. PubMed ID: 11396226
[TBL] [Abstract][Full Text] [Related]
16. Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma.
De Vita F; Orditura M; Lieto E; Infusino S; Morgillo F; Martinelli E; Castellano P; Romano C; Ciardiello F; Catalano G; Pignatelli C; Galizia G
Cancer; 2004 Jan; 100(2):270-8. PubMed ID: 14716760
[TBL] [Abstract][Full Text] [Related]
17. Comparison of angiogenic factor levels in tumor drainage and peripheral venous blood from colorectal cancer patients.
Tien YW; Chang KJ; Chiu YF; Huang KW; Lee PH
Ann Surg Oncol; 2006 Nov; 13(11):1357-63. PubMed ID: 17001510
[TBL] [Abstract][Full Text] [Related]
18. High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment.
Urbańska-Ryś H; Robak T
Mediators Inflamm; 2003 Aug; 12(4):229-35. PubMed ID: 14514474
[TBL] [Abstract][Full Text] [Related]
19. Serum endostatin predicts tumor vascularity in hepatocellular carcinoma.
Dhar DK; Ono T; Yamanoi A; Soda Y; Yamaguchi E; Rahman MA; Kohno H; Nagasue N
Cancer; 2002 Nov; 95(10):2188-95. PubMed ID: 12412173
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie.
Negrier S; Perol D; Menetrier-Caux C; Escudier B; Pallardy M; Ravaud A; Douillard JY; Chevreau C; Lasset C; Blay JY;
J Clin Oncol; 2004 Jun; 22(12):2371-8. PubMed ID: 15197198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]